<DOC>
	<DOCNO>NCT00721669</DOCNO>
	<brief_summary>Primary objective evaluate safety PK IMGN388</brief_summary>
	<brief_title>A Phase I Dose-Escalation Study IMGN388 Patients With Solid Tumors</brief_title>
	<detailed_description>The secondary objective assess pharmacodynamics , immunogenicity , tumor response IMGN388 administer IV infusion every three week patient solid tumor</detailed_description>
	<criteria>Male female age great 18 year Signed informed consent ( ) : Patients must provide informed consent study participation prior perform studyspecific procedure Histologically confirm solid tumor metastatic unresectable standard curative palliative measure exist longer effective Specifically dose expansion phase , enrollment limit patient αv integrin positive melanoma carcinoma breast , lung , ovary . Patients must also confirmation αv integrin expression perform prior enrollment immunohistochemical assessment αv integrin archive available , freshly collect tumor biopsy sample . αv integrin positive tumor define stain intensity least 2+ stain uniformity heterogeneous ( 25 75 % tumor cell stain positively αv integrin ) homogeneous stain ( &gt; 75 % tumor cell positive αv integrin ) tumor cell evaluate immunohistochemistry . Evidence measurable evaluable metastatic disease baseline Eastern Cooperative Oncology Group ( ECOG ) Performance Status score less equal 2 Adequate bone marrow , liver , renal function time first dose study agent , describe : Hemoglobin great equal 9.0 g/dL ( 5.6 mmol/L ; 90 g/L ) without transfusion dependency Absolute neutrophil count ( ANC ) great equal 1.5 x 109/L ( 1500/mm3 ) without hematopoietic cytokine support Platelets great equal 100,000 x 109/L ( 100,000/mm3 ) without transfusion dependency Coagulation [ prothrombin time ( PT ) international normalize ratio ( INR ) activate partial prothrombin time ( aPTT ) ] ≤ 1.25 x upper limit normal ( ULN ) Alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) ≤ 2.5 x ULN liver metastasis ; ≤ 5 x ULN liver metastasis Total Bilirubin ≤ 1.5 x ULN Serum creatinine ≤ 1.5 x ULN Female patient must postmenopausal ( least 12 month since last menses ) , surgically sterile , abstinent , , sexually active , practice effective method birth control ( e.g. , prescription oral contraceptive , contraceptive injection , intrauterine device , doublebarrier method , contraceptive patch , male partner sterilization ) study entry , duration study participation , three month last infusion study agent must negative urine serum pregnancy test within 1 week begin treatment study specify timepoints throughout study . Men must sterilize agree use doublebarrier method birth control must agree donate sperm study three month last infusion study agent . Able adhere study visit schedule protocol requirement The anticipated life expectancy patient expect able participate duration study Patients meet follow criterion may enrol study : Residual toxicity result previous therapy ≥ Grade 1 Neuropathy &gt; Grade 1 History uveitis within 6 month first dose study agent present uveitis baseline Concomitant prior malignancy ( one study ) except adequately treat basal cell squamous cell carcinoma skin carcinoma situ cervix Patients solid tumor history active bleeding Treatment systemic cancer therapy , radiotherapy investigational agent within 4 week five halflives ( whichever longer ) first dose study agent Known allergy clinically important reaction human proteins therapeutic antibody Major surgery within 4 week first dose study agent , plan surgery ( except minor surgical procedure ) study , plan major surgery within 8 week last dose study agent Serious concurrent illness ( medical psychiatric ) , alter mental status ( e.g. , dementia ) uncontrolled medical condition ( eg , uncontrolled diabetes ) , include presence laboratory abnormality , would place patient unacceptable risk participate study would confound ability interpret data study Uncontrolled infection , clinically important active infection within 4 week first dose study agent , currently receive treatment infection Active angina pectoris New York Heart Association ( NYHA ) Class III IV heart disease . Cardiac disease characterize significant ischemic coronary disease , significant arrhythmia , congestive heart failure ( great NYHA Class II ) myocardial infraction within past 6 month Known symptomatic central nervous system ( CNS ) metastases Known seropositive human immunodeficiency virus ( HIV ) , active Hepatitis A , B , C infection Any concomitant anticancer treatment immunotherapy , biotherapy , radiotherapy , chemotherapy , investigative therapy , highdose steroid ; however , lowdose steroid Luteinizing Hormone Releasing Hormone ( LHRH ) dose stable ≥ 14 day permit patient prostate cancer Any medical condition , opinion investigator , may compromise safety patient ability receive study treatment Pregnant lactate woman Patients continue follow short term followup long term survival .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2013</verification_date>
	<keyword>solid tumor</keyword>
</DOC>